Serum serial number 1.3
Diagnosis of smoldering multiple myeloma. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM et al.
#Serum serial number 1.3 trial#
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Leukemia 2003 17: 775–779.īarlogie B, van Rhee F, Shaughnessy JD, Epstein J, Yaccoby S, Pineda-Roman M et al. Thalidomide as initial therapy for early-stage myeloma. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G et al. We conclude that a high FLC ratio ⩾100 is a predictor of imminent progression in SMM, and such patients may be considered candidates for early treatment intervention. The risk of progression to MM within the first 2 years in patients with an FLC ratio ⩾100 was 72% the risk of progression to MM or light chain amyloidosis in 2 years was 79%. The median time to progression in the FLC ratio ⩾100 group was 15 months versus 55 months in the FLC <100 group ( P<0.0001). Fifty-six percent of patients developed progressive disease during median follow-up of 52 months, but this increased to 98% in the subgroup of patients with FLC ratio ⩾100. Receiver operating characteristics analysis determined the optimal FLC ratio cut-point to predict progression to symptomatic multiple myeloma (MM) within 2 years of diagnosis, which resulted in a specificity of 97% and sensitivity of 16%. A serum involved/uninvolved FLC ratio ⩾100 was used to define high-risk SMM, which included 15% ( n=90) of the total cohort. We retrospectively studied the predictive value of the serum (FLC) assay in 586 patients with SMM diagnosed between 1970 to 2010.
#Serum serial number 1.3 free#
A markedly elevated serum free light chain (FLC) ratio may serve as a biomarker for malignant transformation in high-risk smoldering multiple myeloma (SMM) and identify patients who are at imminent risk of progression.